RxDoctor Payments DataLook up a doctor →

Timothy Huyck, MD

Internal Medicine · Papillion, NENPI 1376760991

Payments from drug & device makers

$701,680in general payments, 2019–2025

Across 165 payments — averaging $4252.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$174K
  • E.r. Squibb & Sons, L.L.C.$118K
  • Daiichi Sankyo Inc.$100K
  • Corcept Therapeutics$94K
  • Bayer$87K
  • GSK$29K
  • plus $99K from 28 others

What the payments were for

  • Food & beverage$85890%
  • Education$9810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$701,680 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$3,303,895
Medicare patients
623
Services billed
136,829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide38$747,939
ImbruvicaIbrutinib44$585,218
TagrissoOsimertinib Mesylate20$332,560
IbrancePalbociclib15$227,670
EliquisApixaban43$48,388
XareltoRivaroxaban57$46,501
Abiraterone Acetate13$21,398
Anastrozole139$1,818
Ondansetron Hcl77$860
Gabapentin63$844
Potassium Chloride74$790
Dexamethasone39$771
Acyclovir64$753
Tamoxifen Citrate40$589
Hydroxyurea29$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$19,767$747,93938 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$4,613$585,21844 claims
AstraZenecaTagrisso$204$332,56020 claims
PfizerIbrance, Eliquis$101$276,05858 claims
Johnson & JohnsonXarelto$14$46,50157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Papillion

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →